Giovanni Martinelli, MD, University in Bologna, Bologna, Italy, elaborates on his study regarding blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (R/R Ph+ ALL). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.